Latest news with #PERTEChip
Business Wire
13 hours ago
- Business
- Business Wire
INBRAIN Neuroelectronics Named 2025 World Economic Forum Technology Pioneer
BARCELONA, Spain--(BUSINESS WIRE)-- INBRAIN Neuroelectronics, a clinical-stage neurotechnology company developing precision brain-computer interfaces (BCIs) powered by graphene, today announced it has been selected as a 2025 Technology Pioneer by the World Economic Forum. The prestigious recognition highlights INBRAIN's groundbreaking work developing intelligent neuroelectronic therapies using graphene to treat neurological disorders with unprecedented precision. Founded in 2020, INBRAIN is pioneering a new class of BCI therapeutics built with graphene, a biocompatible material that enables ultra-thin, minimally invasive implants capable of decoding and modulating brain signals in real time at micrometric precision. The company's platform is built to deliver autonomous therapeutics for neurological conditions such as epilepsy, Parkinson's disease, and stroke rehabilitation, using real-time neural data to personalize treatment and ultimately enable reimbursement based on outcomes. 'We are honored to be recognized as a Technology Pioneer by the World Economic Forum,' said Carolina Aguilar, Ph.D., Co-Founder and CEO of INBRAIN Neuroelectronics. 'This award validates our vision to build a new standard of care for patients with neurological disorders, one that is adaptive, precise, and grounded in both data and biology.' Each year, the World Economic Forum selects a limited number of early-stage companies from around the world that are redefining industries through breakthrough technologies and bold business models; past recipients include companies in AI, biotech, and tech, such as Google. As a 2025 Technology Pioneer, INBRAIN will engage directly with global leaders and policymakers at key Forum gatherings, contributing to initiatives that shape the future of health, neurotechnology, and precision medicine. This year's cohort includes 100 innovative startups, with upcoming opportunities to connect at the Annual Meeting of the New Champions in Tianjin, China, and a community convening in New York this December. INBRAIN was recently awarded a €4 million grant by the Spanish Ministry of Industry and Tourism through the PERTE Chip initiative. The grant will accelerate INBRAIN's development of BCI technology that integrates intelligent computing and graphene-based materials to decode and modulate real time brain activity for therapeutic purposes. About INBRAIN Neuroelectronics INBRAIN Neuroelectronics is advancing real-time precision neurology with the world's first graphene-based brain-computer interface therapeutics (BCI-Tx) platform. Using high-resolution neural decoding and targeted micromodulation, INBRAIN delivers personalized, adaptive treatments for neurological conditions like Parkinson's disease, epilepsy, and stroke rehabilitation. The company is developing autonomous BCI therapeutics that continuously monitor and adjust therapy in real time to enhance outcomes and minimize side effects, and has earned FDA Breakthrough Device Designation for its application in Parkinson's disease. In partnership with Merck KGaA and through its subsidiary INNERVIA Bioelectronics, INBRAIN is also developing bioelectronic therapies for peripheral and systemic diseases. Learn more at
Business Wire
06-05-2025
- Business
- Business Wire
INBRAIN Neuroelectronics Awarded €4 Million Grant from Spain's PERTE Chip Program to Advance Graphene-Based Brain-Computer Interfaces
BARCELONA, Spain--(BUSINESS WIRE)-- INBRAIN Neuroelectronics, a clinical-stage neurotechnology company developing precision brain-computer interfaces (BCIs) powered by graphene, announced today it has been awarded a €4 million grant by the Spanish Ministry of Industry and Tourism through the PERTE Chip initiative. The grant will accelerate INBRAIN's development of brain-computer interface technology that integrates intelligent computing and graphene-based materials to decode and modulate real time brain activity for therapeutic purposes. The PERTE Chip initiative - 'Strategic Project for Economic Recovery and Transformation of Microelectronics and Semiconductors' - aims to strengthen the design and production capabilities of the microelectronics and semiconductor industry in Spain from a comprehensive perspective, while promoting strategic technological autonomy for both Spain and the European Union. The Ministry provisionally awarded €53.2 million in funding on May 5, 2025, to support 37 breakthrough projects across 11 autonomous communities. INBRAIN's project was one of several selected for their high-impact potential in areas including disruptive materials, semiconductor manufacturing, cybersecurity, and AI-based computing tools. 'We are honored to receive this national support as part of Spain's effort to lead in cutting-edge neurotechnology,' said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. 'This grant will enable us to accelerate our mission to develop precision neurotechnologies that can transform the treatment of neurological diseases, while also helping to position Spain at the forefront of deep tech innovation in healthcare.' 'INBRAIN Neuroelectronics represents exactly the kind of cutting-edge innovation we aim to support from the Government of Catalonia,' said Mr Miquel Sàmper, regional Minister of Business and Labor. 'By combining advanced materials like graphene and neurotechnology, INBRAIN is not only pushing the boundaries of healthcare innovation, but also strengthening Catalan, Spain and Europe's leadership in strategic deep tech sectors. Supporting projects like this is essential to building the country's technological autonomy and long-term competitiveness in the medtech industry.' INBRAIN's technology platform uses graphene neural interfaces to deliver ultra-precise, adaptive, and biocompatible neuromodulation for a range of conditions including, Parkinson's disease, stroke rehabilitation, epilepsy and in the future neuropsychiatric disorders. About INBRAIN Neuroelectronics INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world's first graphene-based brain-computer interface therapeutics (BCI-Tx) platform. Our technology combines advanced neural decoding and micrometric modulation to deliver personalized, adaptive treatments for conditions like Parkinson's, epilepsy, and stroke rehabilitation. By continuously monitoring and adjusting therapies in real-time, our AI-driven platform enhances outcomes while reducing side effects. This pioneering and disruptive development has led to a FDA Breakthrough Device Designation for INBRAIN's BCI-Tx in Parkinson's Disease. In collaboration with partners like Merck KGaA and our subsidiary INNERVIA Bioelectronics, we are expanding these innovations to treat peripheral nerve and systemic diseases, driving the future of neurotechnology and bioelectronics. Visit us at
